Back to search
Publication

Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.

Abstract

Thalidomide and analogues are a class of immunomodulatory drugs or IMiDS. Thalidomide was initially approved by the U.S. Food and Drug Administation for treatment of erythema nodosum in leprosy and is now approved for multiple myeloma as well. A second generation IMiD, lenalidomide, is also approved for multiple myeloma and refractory myelodysplastic syndrome. Discovery of this class of drugs has been serendipitous and empirical, as the drug targets have been unknown. In this review, the authors integrate recent identification of drug targets of IMiDS, which include the inducible form of nitric oxide synthase (iNOS), Rho GTPase and caspase-1, with the developments in the understanding of the molecular biology of human inflammatory, infectious and neoplastic skin disorders. Because thalidomide reemerged through leprosy, the original disease classified by the T cell, the authors have also emphasized advances in the understanding of T-cell subsets in human skin disorders.

More information

Type
Journal Article
Author
Ladizinski B
Shannon EJ
Sanchez MR
Levis WR
Year of Publication
2010
Journal
Journal of drugs in dermatology : JDD
Volume
9
Issue
7
Number of Pages
814-26
Date Published
2010 Jul
Language
eng
ISSN Number
1545-9616
DOI
10.1136/bmj.c3651
Alternate Journal
J Drugs Dermatol
Publication Language
eng